Search research articles
Contact Us
Filters
Showing results (211-220 of 306) with videos related to
Page
of 31
Sort By:
British Journal of Haematology
|
April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Leukemia & Lymphoma
|
October 2, 2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Amer M Zeidan, Xin Hu, Weiwei Zhu, et al.
Blood Advances
|
May 21, 2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Amer M Zeidan, Rong Wang, Xiaoyi Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Cancer Chemotherapy and Pharmacology
|
February 25, 2025
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
Susan C Scott, Anna Farago, W Victoria Lai, et al.
Cancer Medicine
|
September 13, 2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Nikolai A Podoltsev, Rong Wang, Rory M Shallis, et al.
Leukemia
|
October 8, 2015
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
G Garcia-Manero, S D Gore, S Kambhampati, et al.
Annals of the New York Academy of Sciences
|
December 13, 1996
Factors affecting topotecan sensitivity in human leukemia samples
S H Kaufmann, S D Gore, L Letendre, et al.
British Journal of Haematology
|
October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
Mark R Litzow, Megan Othus, Larry D Cripe, et al.
British Journal of Haematology
|
February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Page
of 31
Search research articles
Search
Showing results (211-220 of 306) with videos related to
Sort By:
Page
of 31
British Journal of Haematology
|
April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Leukemia & Lymphoma
|
October 2, 2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Amer M Zeidan, Xin Hu, Weiwei Zhu, et al.
Blood Advances
|
May 21, 2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Amer M Zeidan, Rong Wang, Xiaoyi Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Cancer Chemotherapy and Pharmacology
|
February 25, 2025
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
Susan C Scott, Anna Farago, W Victoria Lai, et al.
Cancer Medicine
|
September 13, 2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Nikolai A Podoltsev, Rong Wang, Rory M Shallis, et al.
Leukemia
|
October 8, 2015
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
G Garcia-Manero, S D Gore, S Kambhampati, et al.
Annals of the New York Academy of Sciences
|
December 13, 1996
Factors affecting topotecan sensitivity in human leukemia samples
S H Kaufmann, S D Gore, L Letendre, et al.
British Journal of Haematology
|
October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
Mark R Litzow, Megan Othus, Larry D Cripe, et al.
British Journal of Haematology
|
February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Page
of 31